These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 33569743)

  • 1. Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review.
    Fields SD; Tung E
    Infect Dis Ther; 2021 Mar; 10(1):165-186. PubMed ID: 33569743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
    D'Angelo AB; Westmoreland DA; Carneiro PB; Johnson J; Grov C
    AIDS Patient Care STDS; 2021 Aug; 35(8):327-334. PubMed ID: 34375141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
    Walensky RP; Horn T; McCann NC; Freedberg KA; Paltiel AD
    Ann Intern Med; 2020 May; 172(9):583-590. PubMed ID: 32150602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Considerations in the Selection of Preexposure Prophylaxis for HIV Prevention in Canada.
    Knox DC; Pilarski R; Dhunna HS; Kaushal A; Adachi JD
    Can J Infect Dis Med Microbiol; 2022; 2022():3913439. PubMed ID: 36081603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
    Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults.
    Mesplède T
    Expert Opin Pharmacother; 2021 Jul; 22(10):1245-1251. PubMed ID: 33691554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
    De Clercq E
    Biochem Pharmacol; 2016 Nov; 119():1-7. PubMed ID: 27133890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial.
    Thurman AR; Schwartz JL; Cottrell ML; Brache V; Chen BA; Cochón L; Ju S; McGowan I; Rooney JF; McCallister S; Doncel GF
    EClinicalMedicine; 2021 Jun; 36():100893. PubMed ID: 34041459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
    Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL
    J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of renal and bone risk factors among individuals prescribed oral pre-exposure prophylaxis for HIV.
    Fields SD; Gruber J; Clue J; Rey GG; Cuervo HD
    IJID Reg; 2023 Mar; 6():68-75. PubMed ID: 36793391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial.
    Cespedes MS; Das M; Yager J; Prins M; Krznaric I; de Jong J; Xiao D; Shao Y; Wong P; Kintu A; Carter C; Hoornenborg E; Ruane P; Phoenix J; Younis I; Halperin J
    Transgend Health; 2024 Feb; 9(1):46-52. PubMed ID: 38312459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
    Robles G; Sauermilch D; Gandhi M; Starks TJ
    AIDS Behav; 2021 Apr; 25(4):1299-1305. PubMed ID: 33206262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial.
    Herrera C; Serwanga J; Else L; Limakatso L; Opoka D; Ssemata AS; Pillay AD; Namubiru P; Seiphetlo TB; Odoch G; Mugaba S; Seatlholo P; Alieu A; Penchala SD; Muhumuza R; Alinde B; Petkov S; O'Hagan K; Callebaut C; Seeley J; Weiss H; Khoo S; Chiodi F; Gray CM; Kaleebu P; Webb EL; Martinson N; Fox J;
    EBioMedicine; 2023 Jul; 93():104648. PubMed ID: 37327677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
    Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
    DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections.
    De Clercq E
    Biochem Pharmacol; 2018 Jul; 153():2-11. PubMed ID: 29225131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate.
    Cevik M; Orkin C
    Curr Opin HIV AIDS; 2018 Jul; 13(4):315-319. PubMed ID: 29528852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.
    Hagins D; Orkin C; Daar ES; Mills A; Brinson C; DeJesus E; Post FA; Morales-Ramirez J; Thompson M; Osiyemi O; Rashbaum B; Stellbrink HJ; Martorell C; Liu H; Liu YP; Porter D; Collins SE; SenGupta D; Das M
    HIV Med; 2018 Nov; 19(10):724-733. PubMed ID: 30101539
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.